BMO Capital lowered the firm’s price target on TrueBlue (TBI) to $10 from $11 and keeps an Outperform rating on the shares. Industry challenges persisted, but TrueBlue reported a better-than-expected quarter with cost containment efforts driving the beat, the analyst tells investors in a research note. Revenue declines were toward the low-end of guidance, with trends worsening in PeopleReady, though these were less worse in the other two segments, BMO added.